Impaired prion replication in spleens of mice lacking functional follicular dendritic cells

Science

Volumn 288, Issue 5469, 2000, Pages 1257-1259

  Montrasio, Fabio ^a   Frigg, Rico ^a   Glatzel, Markus ^a   Klein, Michael A ^a   Mackay, Fabienne ^b   Aguzzi, Adriano ^a   Weissmann, Charles ^c  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b BIOGEN   (United States)

^c IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; MOUSE; NONHUMAN; PRION; PRIORITY JOURNAL; SCRAPIE; SPLEEN; STROMA; T LYMPHOCYTE; VIRUS INFECTION; VIRUS REPLICATION;

ANIMALS; CELL DIFFERENTIATION; DENDRITIC CELLS, FOLLICULAR; IMMUNOGLOBULINS; LYMPHOTOXIN BETA RECEPTOR; LYMPHOTOXIN-ALPHA; MICE; MICE, INBRED C57BL; MICE, SCID; PRPSC PROTEINS; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; SCRAPIE; SIGNAL TRANSDUCTION; SPLEEN; VIRUS REPLICATION;

EID: 0034686002     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.288.5469.1257     Document Type: Article

References (46)

1. K. I. O'Rourke, T. P. Huff, C. W. Leathers, M. M. Robinson, J. R. Gorham, J. Gen. Virol. 75, 1511 (1994).
2. H. Fraser et al., J. Gen. Virol. 77, 1935 (1996).
3. K. L. Brown, K. Stewart, M. E. Bruce, H. Fraser, J. Gen. Virol. 78, 2707 (1997).
4. C. I. Lasmezas et al., J. Virol. 70, 1292 (1996).
5. M. A. Klein et al., Nature 390, 687 (1997).
6. A. J. Raeber et al., EMBO J. 18, 2702 (1999).
7. H. Fraser and C. F. Farquhar, Vet. Microbiol. 13, 211 (1987).
8. H. Fraser, C. F. Farquhar, I. McConnell, D. Davies, Prog. Clin. Biol. Res. 317, 653 (1989).
9. K. L Brown et al., Nature Med. 1308 (1999).
10. T. Kitamoto, T. Muramoto, S. Mohri, K. Dohura, J. Tateishi, J. Virol. 65, 6292 (1991).
11. P. A. McBride, P. Eikelenboom, G. Kraal, H. Fraser, M. E. Brace, J. Pathol. 168, 413 (1992).
12. T. Muramoto, T. Kitamoto, J. Tateishi, I. Goto, Am. J. Pathol. 140, 1411 (1992).
13. M. A. Klein et al., Nature Med. 4, 1429 (1998).
14. M. Matsumoto et al., J. Exp. Med. 186, 1997 (1997).
15. M. B. Alimzhanov et al., Proc. Natl. Acad. Sci. U.S.A. 94, 9302 (1997).
16. P. A. Koni et al., Immunity 6, 491 (1997).
17. C. F. Ware, S. VanArsdale, T. L. VanArsdale, J. Cell. Biochem. 60, 47 (1996).
18. J. L. Browning et al., J. Immunol. 154, 33 (1995).
19. J. L. Browning et al., Cell 72, 847 (1993).
20. F. Mackay, G. R. Majeau, P. Lawton, P. S. Hochman, J. L Browning, Eur. J. Immunol. 27, 2033 (1997).
21. M. Gonzalez, F. Mackay, J. L Browning, M. H. Kosco-Vilbois, R. J. Noelle, J. Exp. Med. 187, 997 (1998).
22. P. D. Crowe, T. L VanArsdale, B. N. Walter, K. M. Dahms, C. F. Ware, J. Immunol. Methods 168, 79 (1994).
23. F. Mackay and J. L. Browning, Nature 395, 26 (1998).
24. Q. Wu et al., J. Exp. Med. 190, 629 (1999).
25. 50 units of Rocky Mountain Laboratory (RML) scrapie prions. Mice were monitored every second day, and scrapie was diagnosed according to standard clinical criteria (6).
26. 50 units of mouse-adapted scrapie prions (RML 4.1). Depletion was maintained by weekly administration of 100 μg of the fusion protein for 8 weeks. A second set of mice were inoculated with prions as above; 300 μg of LTβR-lg were injected 1 week later and 100 μg LTβR-lg were injected once a week for a further 6 weeks. Three mice from each group were culled 1, 3, and 8 weeks after inoculation, respectively. As control, C57BL/6 mice were subjected to the same regime with a human IgG polyclonal preparation (hulgG, Sandoglobulin) instead of LTβR-lg.
27. F. Montrasio et al., data not shown.
28. M. Kosco-Vilbois, personal communication.
29. R. E. Race and D. Ernst, J. Gen. Virol. 73, 3319 (1992).
30. K. U. Grathwohl, M. Horiuchi, N. Ishiguro, M. Shinagawa, Arch. Virol. 141, 1863 (1996).
31. M. E. Bruce, J. Gen. Virol. 66, 2517 (1985).
32. R. Rubenstein et al., J. Infect. Dis. 164, 29 (1991).
33. M. C. Clarke, Res. Vet. Sci. 12, 195 (1984).
34. Spleen homogenates (10% w/v) from frozen tissues were prepared in 2% sarkosyl-phosphate-buffered saline (PBS). Homogenates were adjusted to 8 mg/ml protein. Total protein (200 μg) of each spleen was treated with proteinase K (20 μg/ml, 30 min, 37°C). Samples were subjected to electrophoresis through an SDS-polyacrylamide gel (12.5%), transferred to nitrocellulose membranes, and probed with polyclonal antiserum 1B3 to mouse PrP (44), and bound antibody was visualized by enhanced chemiluminescence (SuperSignal West Dura Extended Duration Substrate, Pierce).
35. S. B. Prusiner et al., Ann. Neurol. 11, 353 (1982).
36. M. Fischer et al., EMBO J. 15, 1255 (1996).
37. S. Brandner et al., Nature 379, 339 (1996).
38. F. Montrasio and C. Weissmann, unpublished observations.
39. M. Beekes, E. Baldauf, H. Diringer, J. Gen. Virol. 77, 1925 (1996).
40. R. H. Kimberlin and C. A. Walker, Virus Res. 12, 213 (1989).
41. ............, Virus Res. 12, 201 (1989).
42. M. Beekes, P. A. McBride, E. Baldauf, J. Gen. Virol. 79, 601 (1998).
43. D. A. Hilton, E. Fathers, P. Edwards, J. W. Ironside, J. Zajicek, Lancet 352, 703 (1998)
44. C. F. Farquhar, R. A. Somerville, L A. Ritchie, J. Virol. Methods 24, 215 (1989).
45. H. Büeler et al., Mol. Med. 1, 19 (1994).
46. We thank M. Kosco for the gift of FDC M1 antibody and C. Musahl for the rabbit anti-PrP antiserum XN. Supported by the Kanton of Zürich and by Schweizerischer Nationalfonds and European Union grants to A.A. and C.W.